Experimental chemotherapeutic agents for the treatment of colorectal carcinoma.
Colorectal cancer is the third leading cause of cancer mortality for men and women in the United States. For the past 40 years fluorouracil has been the only agent with significant activity in this disease. More recently, advances in our understanding of the molecular biology of cancer have permitted the development of effective new agents for this disease. This article examines the current and future status of these new agents.
O'Reilly
S
S
Division of Medical Oncology, Johns Hopkins Oncology Center, Baltimore, Maryland, USA.
Rowinsky
E K
EK
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D015507:Drugs, Investigational / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D017671:Platinum Compounds / Q000627:therapeutic use; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D059004:Topoisomerase I Inhibitors
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D017671:Platinum Compounds; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D013940:Thymidylate Synthase; D008666:Metalloendopeptidases; D005472:Fluorouracil; D002166:Camptothecin